TNFSF14 Specific Neutra™ Antibody Products
Product listThe Tumor Necrosis Factor Superfamily Member TNFSF14, also referred to as CD258 and LIGHT, is a secreted protein belonging to the TNF superfamily. Around 29 kD in size, this protein might serve as a co-stimulatory factor for lymphoid cell activation and act as a barrier against herpesvirus infection.
Its Gene ID: 8740, UniProtKB ID: O43557, and OMIM ID: 604520.
The Role of TNFSF14 in Immunity
TNFSF14, which exhibits homology with lymphotoxin, competes with Herpes Simplex Virus glycoprotein D for binding to Herpes Virus Entry Mediator (HVEM). Predominantly found in activated T cells, activated Natural Killer (NK) cells, and immature dendritic cells (DCs), HVEM serves as a dual-functioning molecule, existing as both a soluble protein and a cell surface-bound type II membrane protein. In its homotrimer, it interacts with both HVEM and Lymphotoxin-β receptors (LTβR). Activation of HVEM leads to T-cell costimulation, whereas LTβR signaling influences the susceptibility of cancer cells to immune responses, facilitates the repair of tumor vasculature, and promotes the trafficking and infiltration of effector cells into tumors. Overall, LIGHT-HVEM primarily drives anti-tumor immune activity, while LIGHT-LTβR builds, repairs, and maintains the infrastructure for these immune responses.
TNFSF14 Antibodies in Cancer Immunotherapy
TNFSF14 has been under pre-clinical development for over a decade and has shown significant promise in enhancing cancer immunotherapy treatments. When TNFSF14 molecules are delivered to or expressed within tumors, they induce substantial changes in the tumor microenvironment. These changes are mainly driven by two key mechanisms: vascular normalization and the generation of tertiary lymphoid structures. Vascular normalization helps to improve the delivery and efficacy of therapeutic agents, while tertiary lymphoid structures play a crucial role in initiating and sustaining anti-tumor immune responses, as shown in Fig.1.
Fig.1 TNFSF14 through different methods modifies the tumor microenvironment.1
TNFSF14 recombinant antibody platforms are designed to enhance its immunostimulatory effects while specifically targeting tumor tissues. This utilizes various strategies to fuse TNFSF14 with short tumor vasculature targeting single-chain fragment variable (scFv) antibodies, which is to achieve dual benefits: inducing a potent anti-tumor immune response through the immunostimulatory function of TNFSF14 and leveraging the precise targeting capabilities of scFv-fused constructs. This targeted approach concentrates therapeutic effects within the tumor microenvironment, enhancing efficacy and reducing potential off-target effects, thereby offering a powerful new approach to cancer treatment.
Services
Creative Biolabs is proud to offer a comprehensive range of anti-TNFSF14 antibody products. These antibodies, meticulously developed through recombinant expression techniques, are designed to meet the diverse needs of scientific research and therapeutic development. Please contact us for more information on our anti-TNFSF14 antibody products and how they can be integrated into your research or therapeutic development projects.
REFERENCE
- Skeate, Joseph G., et al. "TNFSF14: LIGHTing the way for effective cancer immunotherapy." Frontiers in immunology 11 (2020): 537705. Under open access license CC BY 4.0, without modification.
